In light of these considerations, our systematic review and meta-analysis aim to comprehensively evaluate the risk of TB disease associated with TNF-α antagonist therapy across various autoimmune diseases and specific TNF-α antagonist drugs. This evidence concerns the gene TNF and autoimmune disease.